All PlansCoverageMedium impact
Pharmacogenomic and Metabolite Markers for Individuals Treated with Thiopurines
Blue Cross & Blue Shield of Mississippi·MS · Gastroenterology, Rheumatology, Oncology +3 more·Medical Policy
We identified it
Jun 20, 2026
Summary
New medical policy A.2.04.19 establishes coverage criteria for pharmacogenomic testing (TPMT/NUDT15) and metabolite monitoring for patients receiving thiopurine medications like azathioprine, mercaptopurine, and thioguanine. The policy provides detailed coverage guidelines for genetic testing to prevent drug toxicity and therapeutic monitoring of drug metabolites.
Action Required
Immediately: Review and understand new policy A.2.04.19 for pharmacogenomic testing coverage. Billing team should verify coverage criteria for TPMT/NUDT15 genetic testing and thiopurine metabolite monitoring when submitting claims. Ensure proper documentation of medical necessity for patients on thiopurine medications (azathioprine, mercaptopurine, thioguanine) who require genetic testing or metabolite monitoring.